FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Endo Paying $1.5 Billion Fines, Forfeitures

Endo is ordered to pay $1.85 billion in fines and forfeitures after pleading guilty to introducing misbranded Opana ER into interstate commerce and cl...

latest-news-card-1
Medical Devices

Multiple Violations in Bioptimal Inspection

FDA warns Chinas Bioptimal International about multiple violations at a Singapore facility manufacturing two unapproved catheters.

latest-news-card-1
Medical Devices

CDRH Product Evaluation/Quality Office Modified

Federal Register notice: FDA announces that CDRH Office of Product Evaluation and Quality has modified its organizational structure.

latest-news-card-1
Human Drugs

FDA OKs TE Code for Paclitaxel Suspension

FDA approves an AB therapeutic equivalence code for cancer drug paclitaxel suspension and tells HBT Labs it must formally apply for a return of PDUFA ...

latest-news-card-1
Federal Register

FDA Debars Runsdorg Over Cough Syrup

Federal Register notice: FDA issues an order permanently debarring Adam Paul Runsdorf over his felony conviction for conspiring to distribute counterf...

latest-news-card-1
Human Drugs

CDER Launches Quantitative Medicine Center

CDER launches a new Quantitative Medicine Center of Excellence to help streamline and accelerate drug development.

latest-news-card-1
FDA General

J&J Reports Favorable TAR-200 Clinical Data

A Phase 2b clinical study evaluating Johnson & Johnsons investigational TAR-200 monotherapy in nonmuscle-invasive bladder cancer patients with carcino...

latest-news-card-1
Human Drugs

GlycoMimetics Phase 3 Leukemia Study Fails

GlycoMimetics says its Phase 3 study of uproleselan plus chemotherapy in acute myeloid leukemia patients did not achieve a statistically significant i...

latest-news-card-1
Human Drugs

REMS Logic Model Draft Guidance

FDA posts a draft guidance entitled REMS Logic Model: A Framework to Link Program Design With Assessment" to help applicants with designing and managi...

latest-news-card-1
Federal Register

12 No-Longer-Marketed ANDAs Withdrawn

Federal Register notice: FDA withdraws approval of 12 ANDAs from multiple applicants after they notified the agency that they were no longer marketed.